The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
Your provider will design a transition plan that may include an overlap period or a gap between medications
Semaglutide offers a safe, effective, and well-rounded approach to weight loss, and when paired with lifestyle changes, it can help individuals achieve lasting success
Burping is a reported gastrointestinal side effect in 15-30% of users, typically peaking in the first 4-6 weeks and improving as your body adapts
Patients with pre-existing gastrointestinal conditions should maintain closer monitoring
Peptides are small chains of amino acids that can signal your body to release or regulate hormones